PTPN12

Summary

PTPN12 (protein tyrosine phosphatase non-receptor type 12, HGNC:9645) is a protein-coding gene on chromosome 7q11.23, encoding Tyrosine-protein phosphatase non-receptor type 12 (Q05209). Dephosphorylates a range of proteins, and thereby regulates cellular signaling cascades.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains a C-terminal PEST motif, which serves as a protein-protein interaction domain, and may regulate protein intracellular half-life. This PTP was found to bind and dephosphorylate the product of the oncogene c-ABL and thus may play a role in oncogenesis. This PTP was also shown to interact with, and dephosphorylate, various products related to cytoskeletal structure and cell adhesion, such as p130 (Cas), CAKbeta/PTK2B, PSTPIP1, and paxillin. This suggests it has a regulatory role in controlling cell shape and mobility. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 5782 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 116 total — 1 pathogenic
• Phenotypes (HPO): 8
• Druggable target: yes
• MANE Select transcript: NM_002835

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9645
Approved symbol	PTPN12
Name	protein tyrosine phosphatase non-receptor type 12
Location	7q11.23
Locus type	gene with protein product
Status	Approved
Aliases	PTPG1, PTP-PEST
Ensembl gene	ENSG00000127947
Ensembl biotype	protein_coding
OMIM	600079
Entrez	5782

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 11 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay

ENST00000248594, ENST00000407343, ENST00000415482, ENST00000418110, ENST00000433369, ENST00000435495, ENST00000440186, ENST00000447995, ENST00000460731, ENST00000464313, ENST00000481154, ENST00000494248, ENST00000519553, ENST00000520947, ENST00000522115, ENST00000523952, ENST00000928330, ENST00000962769, ENST00000962770

RefSeq mRNA: 3 — MANE Select: NM_002835 NM_001131008, NM_001131009, NM_002835

CCDS: CCDS47619, CCDS47620, CCDS5592

Canonical transcript exons

ENST00000248594 — 18 exons

Exon	Start	End
ENSE00000698025	77600664	77600806
ENSE00000698037	77618480	77618565
ENSE00000698040	77626705	77627675
ENSE00001560540	77639219	77640069
ENSE00001819992	77537295	77537645
ENSE00002476263	77637018	77637048
ENSE00002510284	77632348	77632425
ENSE00002526805	77635782	77635849
ENSE00003466075	77571078	77571186
ENSE00003489504	77607235	77607301
ENSE00003520651	77585543	77585581
ENSE00003542684	77581427	77581503
ENSE00003614615	77610948	77611046
ENSE00003634532	77638624	77638731
ENSE00003636482	77583555	77583650
ENSE00003676521	77597842	77597901
ENSE00003691752	77610765	77610842
ENSE00003786473	77592185	77592256

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 98.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.8469 / max 339.4932, expressed in 1757 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79209	5.2774	1389
79207	3.9323	1353
79208	2.3083	1125
79210	1.1664	710
79211	0.8282	398
79212	0.6481	347
79213	0.5488	264
79216	0.1373	62

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	98.60	gold quality
colonic epithelium	UBERON:0000397	98.48	gold quality
monocyte	CL:0000576	98.06	gold quality
mononuclear cell	CL:0000842	97.93	gold quality
right lung	UBERON:0002167	97.88	gold quality
leukocyte	CL:0000738	97.73	gold quality
nerve	UBERON:0001021	97.26	gold quality
tibial nerve	UBERON:0001323	97.26	gold quality
calcaneal tendon	UBERON:0003701	96.91	gold quality
lower lobe of lung	UBERON:0008949	96.62	gold quality
upper lobe of lung	UBERON:0008948	96.60	gold quality
upper lobe of left lung	UBERON:0008952	96.59	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.58	gold quality
ventricular zone	UBERON:0003053	96.57	gold quality
visceral pleura	UBERON:0002401	96.54	gold quality
ganglionic eminence	UBERON:0004023	96.54	gold quality
tibia	UBERON:0000979	96.44	gold quality
omental fat pad	UBERON:0010414	96.36	gold quality
peritoneum	UBERON:0002358	96.34	gold quality
lung	UBERON:0002048	96.21	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.21	gold quality
popliteal artery	UBERON:0002250	95.91	gold quality
tibial artery	UBERON:0007610	95.91	gold quality
right coronary artery	UBERON:0001625	95.90	gold quality
adipose tissue	UBERON:0001013	95.85	gold quality
ectocervix	UBERON:0012249	95.82	gold quality
connective tissue	UBERON:0002384	95.79	gold quality
sural nerve	UBERON:0015488	95.78	gold quality
cartilage tissue	UBERON:0002418	95.76	gold quality
pleura	UBERON:0000977	95.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

150 targeting PTPN12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-188-3P	100.00	68.76	1240
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-300	99.92	71.76	2856

Literature-anchored findings (GeneRIF, showing 40)

• PTP-PEST actively contributes to the cellular apoptotic response and reveal the importance of caspases as regulators of PTPs in apoptosis. (PMID:17130234)
• These data demonstrate that LPXN forms a signaling complex with Pyk2, c-Src, and PTP-PEST to regulate migration of prostate cancer cells. (PMID:17329398)
• No association was detected between individual PTPN12 tag SNPs and GD but preliminary evidence suggests PTPN12 confers an increased risk of mild/moderate ophthalmopathy (NOSPECS classes 2-4) and that PTPN12 interacts with the TSHR. (PMID:17608818)
• conclusion: protein phosphatase 1alpha associates with the non-catalytic domain of protein tyrosine phosphatase-PEST (PTP-PEST)and regulates PTP activity via dephosphorylation of phospho-Ser39 (PMID:19919952)
• PTP-PEST functions as a suppressor of epithelial cell motility by controlling Rho GTPase activity and the assembly of adherens junctions. (PMID:20519451)
• Using a genetic screen, study identifies the PTPN12 tyrosine phosphatase as a tumor suppressor in (PMID:21376233)
• Suggest PTPN12 and ERK5 mediate HER2-driven cell motility in ovarian cancer cells, through FAK targeting. (PMID:21483099)
• activated Ras induces extracellular signal-regulated kinase 1 and 2-dependent phosphorylation of PTP-PEST at S571, which recruits PIN1 to bind to PTP-PEST (PMID:21876001)
• High expression of PTPN12 is associated with favorable disease free survival in esophageal squamous cell carcinoma patients. (PMID:22429674)
• Studies indicate that CD45, nonreceptor SH2 domain-containing PTP-1 (SHP-1) and PEST domain-enriched tyrosine phosphatase (PEP) are expressed at elevated levels in immune cells and play essential roles in T cell homeostasis. (PMID:22458809)
• This report identifies two additional PTPs, SHP-2 and PTP-PEST, that are also directly activated by the Rb-E2F pathway and which can contribute to signal transduction during p53-independent apoptosis (PMID:22644489)
• PTPN12 is potentially a methylation-silenced TSG for breast cancer that may play an important role in breast carcinogenesis and could potentially serve as an independent prognostic factor for invasive breast cancer patients. (PMID:23044628)
• The involvement of PTPN12 in the antioxidant response of breast cancer cells suggests that PTPN12 may represent a novel therapeutic target for this disease (PMID:23435421)
• Overexpression of PTPN12 inhibited proliferation and migration in OSCC cells. (PMID:23733313)
• MRNAs of PTPN12, MSH6, and ZEB1 orthologous genes from different animal species have binding sites for hsa-miR-1279 which consist of homologous oligonucleotides encoding similar human oligopeptides (PMID:23957009)
• these data suggest that PTP-PEST affects epithelial cell motility by controlling the distribution and phosphorylation of p120 and its availability to control Rho GTPase activity. (PMID:24284071)
• the activity of SHP-2, PTP-1beta, and PTP-PEST was enhanced by LKB1-expressing cells. (PMID:24285539)
• Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. (PMID:24475046)
• The decrease expression of PTPN12 might be important in conferring a more aggressive behavior in NPC. Thus, PTPN12 expression may be used as a novel independent prognostic biomarker for patients with NPC. (PMID:25663493)
• Study suggests that PTPN12 expression is a valuable prognostic biomarker for non-small cell lung cancer. (PMID:25868976)
• PTPN12 expression decreases in human renal cell carcinoma (PMID:26537073)
• PTP-PEST regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP controlling EphA3 phosphorylation. (PMID:26644181)
• this study, with a relative large population, showed that PTPN12 eQTL SNP may interact with HBV mutation on HCC risk. (PMID:27075395)
• MyoVa-Ca(2+) channel interactions are required for proper long-range axon growth in developing spinal cord in vivo. (PMID:27134172)
• identified a new phosphorylation-based substrate recognition mechanism of PTPN12 by CDK2, which orchestrated signaling crosstalk between the oncogenic CDK2 and HER2 pathways (PMID:28842430)
• Here, solved is a crystal structure of the native PTPN12 catalytic domain with the catalytic cysteine (residue 231) in dual conformation (phosphorylated and unphosphorylated). (PMID:29278368)
• PTPN12 plasmid transfection increased PTPN12 mRNA and protein expressions, suppressed cell proliferation and migration, reduced EGFR level, and enhanced caspase 3 activity compared with control and empty plasmid groups. (PMID:29634414)
• PTPN12, PTPRN and PTPN18 were independent prognostic factors in Hepatocellular Carcinoma. (PMID:29742497)
• PTPN12 balances GBM cell growth. (PMID:29743287)
• These results show that ROS-induced oxidation of PTPN12 accounts for ABL1 phosphorylation in HLRCC-associated PRCC, revealing a novel mechanism for inactivating a tumor suppressor gene product and establishing a direct link between pathologic PTP oxidation and neoplastic disease. (PMID:30297534)
• PTPN12 rs3750050 could impair the inhibitory effect of PTPN12 on Ras/MEK/ERK signaling by impeding SHC dephosphorylation, increase the expression of cyclin D1 and ultimately lead to aberrant cell proliferation, thus contributing to colorectal cancer pathogenesis. (PMID:30731403)
• This review provides an overview of PTPN12 and discusses the critical roles of PTPN12 in tumor progression. [review] (PMID:30959160)
• Molecular docking analysis provide evidence that PTPN12 protein interacts with AIFM3 protein. (PMID:31088422)
• This study identifies PTPN12 expression measurement as a valuable prognostic marker in prostate cancer. (PMID:31606028)
• tumor suppressing gene [review] (PMID:32541467)
• Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma. (PMID:33292053)
• The protein tyrosine phosphatase PTP-PEST mediates hypoxia-induced endothelial autophagy and angiogenesis via AMPK activation. (PMID:33323505)
• Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma. (PMID:34784010)
• PTP-PEST Regulated Membranous/Cytoplasmic Translocation of p120ctn in the Lung Cancer Resistance to Tyrosine Kinase Inhibitor. (PMID:35030104)
• Protein tyrosine phosphatase non-receptor type 12 suppresses tumor progression in osteosarcoma cells. (PMID:35063332)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ptpn12	ENSMUSG00000028771
rattus_norvegicus	Ptpn12	ENSRNOG00000013135

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Tyrosine-protein phosphatase non-receptor type 12 — Q05209 (reviewed: Q05209)

Alternative names: PTP-PEST, Protein-tyrosine phosphatase G1

All UniProt accessions (8): Q05209, C9J1X8, C9JJC1, C9JYA4, F8WB51, H0YB59, H0YC15, H3BM04

UniProt curated annotations — full annotation on UniProt →

Function. Dephosphorylates a range of proteins, and thereby regulates cellular signaling cascades. Dephosphorylates cellular tyrosine kinases, such as ERBB2 and PTK2B/PYK2, and thereby regulates signaling via ERBB2 and PTK2B/PYK2. Selectively dephosphorylates ERBB2 phosphorylated at ‘Tyr-1112’, ‘Tyr-1196’, and/or ‘Tyr-1248’.

Subunit / interactions. Interacts with TGFB1I1. Interacts with PSTPIP1. Interacts with PTK2B/PYK2. Interacts with LPXN. Interacts with SORBS2; this interaction greatly enhances WASF1 dephosphorylation and might mediate partial translocation to focal adhesion sites.

Subcellular location. Cytoplasm. Cell junction. Focal adhesion. Cell projection. Podosome.

Post-translational modifications. Phosphorylated by STK24/MST3 and this results in inhibition of its activity.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class 4 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q05209-1	1	yes
Q05209-2	2
Q05209-3	3

RefSeq proteins (3): NP_001124480, NP_001124481, NP_002826* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR012266	PTN12	Family
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR047170	PTN12/18/22	Family
IPR047251	PTN12_cat	Domain

Pfam: PF00102

Enzyme classification (BRENDA):

• EC 3.1.3.16 — protein-serine/threonine phosphatase (BRENDA: 92 organisms, 641 substrates, 468 inhibitors, 127 Km, 67 kcat entries)
• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

129 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.023–0.862	22
P-NITROPHENYL PHOSPHATE	0.0024–10	20
4-NITROPHENYL PHOSPHATE	0.0028–12.7	13
DADEPYLIPQQG	0.0003–0.1	12
P-NITROPHENYL PHOSPHATE	3–200	11
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
RRAPTVA	0.058–1.954	4
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
PHOSPHOCASEIN	0.0001–0.002	3
PHOSPHOHISTONE	0.0023–0.0723	3

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (84 total): modified residue 20, strand 12, mutagenesis site 10, helix 10, compositionally biased region 9, binding site 5, region of interest 4, sequence variant 4, turn 3, splice variant 2, sequence conflict 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5HDE	X-RAY DIFFRACTION	1.62
5J8R	X-RAY DIFFRACTION	2.04
5O2P	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q05209-F1	63.20	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 231 (phosphocysteine intermediate)

Ligand- & substrate-binding residues (5): 36; 63–67; 199; 231–237; 278

Post-translational modifications (20): 1, 19, 332, 435, 449, 468, 509, 519, 567, 569, 571, 596, 598, 603, 606, 608, 613, 673, 689, 693

Mutagenesis-validated functional residues (10):

Position	Phenotype
19	loss of phosphorylation site.
36	decreases enzyme activity.
63	decreases enzyme activity.
64	abolishes enzyme activity.
66	abolishes enzyme activity.
67	nearly abolishes enzyme activity.
199	abolishes enzyme activity.
200	decreases enzyme activity.
270	decreases enzyme activity.
278	nearly abolishes enzyme activity.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1250196	SHC1 events in ERBB2 signaling
R-HSA-182971	EGFR downregulation
R-HSA-186797	Signaling by PDGF
R-HSA-8863795	Downregulation of ERBB2 signaling
R-HSA-9008059	Interleukin-37 signaling
R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2

MSigDB gene sets: 398 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_PLATELET_DERIVED_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GGGACCA_MIR133A_MIR133B, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, TAATAAT_MIR126, WANG_CLIM2_TARGETS_UP, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, TGCGCANK_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_NEGATIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY, MODULE_45, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN

GO Biological Process (8): protein dephosphorylation (GO:0006470), peptidyl-tyrosine dephosphorylation (GO:0035335), regulation of epidermal growth factor receptor signaling pathway (GO:0042058), tissue regeneration (GO:0042246), cellular response to epidermal growth factor stimulus (GO:0071364), negative regulation of ERBB signaling pathway (GO:1901185), negative regulation of platelet-derived growth factor receptor-beta signaling pathway (GO:2000587), dephosphorylation (GO:0016311)

GO Molecular Function (6): phosphoprotein phosphatase activity (GO:0004721), protein tyrosine phosphatase activity (GO:0004725), non-membrane spanning protein tyrosine phosphatase activity (GO:0004726), SH3 domain binding (GO:0017124), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (8): podosome (GO:0002102), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), focal adhesion (GO:0005925), cell projection (GO:0042995), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Signaling by ERBB2	2
Signaling by EGFR	1
Signaling by Receptor Tyrosine Kinases	1
Interleukin-1 family signaling	1
Signaling by ERBB2 in Cancer	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of ERBB signaling pathway	2
dephosphorylation	1
protein modification process	1
protein dephosphorylation	1
epidermal growth factor receptor signaling pathway	1
regeneration	1
developmental growth	1
response to epidermal growth factor	1
cellular response to growth factor stimulus	1
negative regulation of signal transduction	1
ERBB signaling pathway	1
negative regulation of platelet-derived growth factor receptor signaling pathway	1
platelet-derived growth factor receptor-beta signaling pathway	1
regulation of platelet-derived growth factor receptor-beta signaling pathway	1
phosphate-containing compound metabolic process	1
phosphatase activity	1
catalytic activity, acting on a protein	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
protein domain specific binding	1
binding	1
catalytic activity	1
actin-based cell projection	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
cell-substrate junction	1
cell junction	1

Protein interactions and networks

STRING

1464 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPN12	PSTPIP1	O43586	995
PTPN12	PTS	Q03393	936
PTPN12	PTK2	Q05397	898
PTPN12	GRB2	P29354	874
PTPN12	BCAR1	P56945	861
PTPN12	PXN	P49023	833
PTPN12	PTK2B	Q14289	831
PTPN12	SRC	P12931	815
PTPN12	LPXN	O60711	783
PTPN12	CSK	P41240	766
PTPN12	TGFB1I1	O43294	653
PTPN12	CRK	P46108	643
PTPN12	WAS	P42768	642
PTPN12	MEFV	O15553	628
PTPN12	ERBB2	P04626	596

IntAct

117 interactions, top by confidence:

A	B	Type	Score
PTPN12	SHC1	psi-mi:“MI:0914”(association)	0.860
PTPN12	SHC1	psi-mi:“MI:0915”(physical association)	0.860
PSTPIP1	PTPN12	psi-mi:“MI:0915”(physical association)	0.830
PTPN12	PSTPIP1	psi-mi:“MI:0915”(physical association)	0.830
PSTPIP1	PTPN12	psi-mi:“MI:0403”(colocalization)	0.830
PTPN12	EGFR	psi-mi:“MI:0915”(physical association)	0.810
EGFR	PTPN12	psi-mi:“MI:0915”(physical association)	0.810
PXN	PTPN12	psi-mi:“MI:0915”(physical association)	0.760
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
SHC1	AP2A1	psi-mi:“MI:0914”(association)	0.730
PDGFRB	PTPN12	psi-mi:“MI:0915”(physical association)	0.700
PTPN12	PDGFRB	psi-mi:“MI:0915”(physical association)	0.700
PTPN12	BCAR1	psi-mi:“MI:0407”(direct interaction)	0.690
PTPN12	BCAR1	psi-mi:“MI:0915”(physical association)	0.690
BCAR1	PTPN12	psi-mi:“MI:0915”(physical association)	0.690
LPXN	PCNT	psi-mi:“MI:0914”(association)	0.640
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
VAPA	FAM83G	psi-mi:“MI:0914”(association)	0.640
CD27	TCAF2	psi-mi:“MI:0914”(association)	0.640

BioGRID (211): PTPN12 (Two-hybrid), PTPN12 (Affinity Capture-MS), PTPN12 (Reconstituted Complex), PTPN12 (Proximity Label-MS), PTPN12 (PCA), PTPN12 (Affinity Capture-Luminescence), PTPN12 (Affinity Capture-MS), PTPN12 (Affinity Capture-MS), PSTPIP1 (Two-hybrid), SHC1 (Two-hybrid), PXN (Two-hybrid), PTPN12 (Two-hybrid), PTPN12 (Two-hybrid), PTPN12 (Two-hybrid), PTPN12 (Two-hybrid)

ESM2 similar proteins: A1L1L3, B3NKK1, B4IMC3, B4NSS9, G5EC24, G5EGA9, G5EGU2, H2KZM6, H2KZW3, O08617, O55082, P04157, P06800, P08575, P18052, P18475, P28192, P29349, P29351, P34138, P34337, P34442, P35235, P41499, P42083, P42159, P81718, Q05209, Q06124, Q10656, Q15256, Q20402, Q22712, Q4JDL3, Q5I124, Q5I128, Q5I137, Q5I138, Q5I139, Q5I141

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

37 interactions.

A	Effect	B	Mechanism
PTPN12	“down-regulates activity”	PTK2B	dephosphorylation
PTPN12	down-regulates	BCAR1	dephosphorylation
PTPN12	down-regulates	PTK2	dephosphorylation
PTPN12	down-regulates	WAS	dephosphorylation
PTPN12	down-regulates	JAK2	dephosphorylation
PTPN12	down-regulates	GIT2	dephosphorylation
PTPN12	“down-regulates activity”	JAK2	dephosphorylation
PRKCA	down-regulates	PTPN12	phosphorylation
PTPN12	“down-regulates activity”	ERBB2	dephosphorylation
PTPN12	“up-regulates activity”	SRC	dephosphorylation
PTPN12	“up-regulates activity”	ARHGDIA	dephosphorylation
CDK2	“down-regulates activity”	PTPN12	phosphorylation
STK24	“down-regulates activity”	PTPN12	phosphorylation
PTPN12	down-regulates	INSR	dephosphorylation
PTPN12	down-regulates	SHC1	dephosphorylation
PTPN12	“down-regulates activity”	ABL1	dephosphorylation
PTPN12	“down-regulates activity”	PSTPIP1	dephosphorylation
PTPN12	“down-regulates activity”	SRC	dephosphorylation
PTPN12	“down-regulates activity”	WAS	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 92 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PI3K events in ERBB2 signaling	6	59.3×	4e-08
Signaling by ERBB2 ECD mutants	5	49.4×	2e-06
Signaling by ERBB2 KD Mutants	7	43.5×	2e-08
SHC1 events in ERBB2 signaling	6	42.0×	3e-07
Signaling by ERBB2 TMD/JMD mutants	6	42.0×	3e-07
Signaling by ERBB2	5	25.4×	6e-05
Constitutive Signaling by Aberrant PI3K in Cancer	12	22.4×	3e-11
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	13	18.5×	3e-11

GO biological processes:

GO term	Partners	Fold	FDR
peptidyl-tyrosine phosphorylation	8	39.6×	4e-09
epidermal growth factor receptor signaling pathway	11	32.1×	3e-11
insulin-like growth factor receptor signaling pathway	5	29.2×	7e-05
positive regulation of receptor signaling pathway via JAK-STAT	5	25.4×	1e-04
cell surface receptor protein tyrosine kinase signaling pathway	12	24.5×	3e-11
B cell receptor signaling pathway	5	23.6×	1e-04
protein autophosphorylation	11	18.8×	3e-09
T cell activation	6	18.3×	7e-05

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	75
Likely benign	10
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
9448	NM_002835.4(PTPN12):c.182A>G (p.Lys61Arg)	Pathogenic

SpliceAI

2476 predictions. Top by Δscore:

Variant	Effect	Δscore
7:77537643:ATGGT:A	donor_loss	1.0000
7:77537644:TG:T	donor_gain	1.0000
7:77537645:GG:G	donor_gain	1.0000
7:77537646:G:GG	donor_gain	1.0000
7:77537646:G:T	donor_loss	1.0000
7:77537647:T:A	donor_loss	1.0000
7:77571070:A:AG	acceptor_gain	1.0000
7:77571075:A:AG	acceptor_gain	1.0000
7:77571075:AAGC:A	acceptor_gain	1.0000
7:77571075:AAGCG:A	acceptor_gain	1.0000
7:77571076:A:G	acceptor_gain	1.0000
7:77571077:GC:G	acceptor_gain	1.0000
7:77571182:GCCAT:G	donor_gain	1.0000
7:77571187:G:GG	donor_gain	1.0000
7:77581422:CGTA:C	acceptor_loss	1.0000
7:77581424:TAGT:T	acceptor_loss	1.0000
7:77581425:A:AG	acceptor_gain	1.0000
7:77581425:AG:A	acceptor_loss	1.0000
7:77581425:AGTT:A	acceptor_gain	1.0000
7:77581426:G:GT	acceptor_gain	1.0000
7:77581426:GT:G	acceptor_gain	1.0000
7:77581426:GTT:G	acceptor_gain	1.0000
7:77581426:GTTG:G	acceptor_gain	1.0000
7:77583549:TTTTA:T	acceptor_loss	1.0000
7:77583550:TTTA:T	acceptor_loss	1.0000
7:77583551:TTAG:T	acceptor_loss	1.0000
7:77583552:TAG:T	acceptor_loss	1.0000
7:77583553:A:AG	acceptor_gain	1.0000
7:77583553:AG:A	acceptor_gain	1.0000
7:77583554:G:A	acceptor_loss	1.0000

AlphaMissense

5159 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:77537640:T:C	F32L	1.000
7:77537642:C:A	F32L	1.000
7:77537642:C:G	F32L	1.000
7:77571082:T:C	L35S	1.000
7:77571085:G:C	R36T	1.000
7:77571086:A:C	R36S	1.000
7:77571086:A:T	R36S	1.000
7:77571107:A:C	R43S	1.000
7:77571107:A:T	R43S	1.000
7:77571164:C:A	N62K	1.000
7:77571164:C:G	N62K	1.000
7:77571166:G:C	R63T	1.000
7:77571167:A:C	R63S	1.000
7:77571167:A:T	R63S	1.000
7:77571168:T:C	Y64H	1.000
7:77571171:A:G	K65E	1.000
7:77571173:G:C	K65N	1.000
7:77571173:G:T	K65N	1.000
7:77571174:G:C	D66H	1.000
7:77571175:A:C	D66A	1.000
7:77571175:A:G	D66G	1.000
7:77571175:A:T	D66V	1.000
7:77571178:T:A	I67K	1.000
7:77571178:T:G	I67R	1.000
7:77571181:T:C	L68P	1.000
7:77571184:C:A	P69Q	1.000
7:77571186:T:C	F70L	1.000
7:77581428:T:A	F70L	1.000
7:77581428:T:G	F70L	1.000
7:77581442:T:A	V75D	1.000

dbSNP variants (sampled 300 via entrez): RS1000016521 (7:77606601 C>A,T), RS1000022577 (7:77626626 C>T), RS1000023033 (7:77566398 T>C), RS1000085571 (7:77606199 C>T), RS1000157280 (7:77541387 G>A), RS1000161102 (7:77581919 G>A), RS1000173438 (7:77622702 C>T), RS1000191049 (7:77591448 T>C), RS1000195797 (7:77565801 A>G), RS1000202703 (7:77576294 T>C), RS1000224436 (7:77572927 A>G), RS1000245172 (7:77554465 A>G), RS1000255466 (7:77572756 T>C,G), RS1000280908 (7:77629074 C>T), RS1000281769 (7:77547271 G>C)

Disease associations

OMIM: gene MIM:600079 | disease phenotypes: MIM:114500

GenCC curated gene-disease

Mondo (2): colorectal cancer (MONDO:0005575), colon carcinoma (MONDO:0002032)

Orphanet (1): NON RARE IN EUROPE: Colorectal cancer (Orphanet:466667)

HPO phenotypes

8 total (8 of 8 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001442	Typified by somatic mosaicism
HP:0002891	Uterine leiomyosarcoma
HP:0003003	Colon cancer
HP:0005584	Renal cell carcinoma
HP:0006716	Hereditary nonpolyposis colorectal carcinoma
HP:0006740	Transitional cell carcinoma of the bladder
HP:0006753	Neoplasm of the stomach

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST007876_54	Estimated glomerular filtration rate	1.000000e-15
GCST010796_2356	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2357	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-09
GCST010796_2358	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_2359	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-09
GCST010796_2360	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2361	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-09
GCST90002388_393	Lymphocyte count	2.000000e-10
GCST90020024_103	A body shape index	3.000000e-08
GCST90020024_106	A body shape index	4.000000e-09
GCST90020025_1116	Waist-to-hip ratio adjusted for BMI	4.000000e-11
GCST90020025_1117	Waist-to-hip ratio adjusted for BMI	1.000000e-08
GCST90020025_1119	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020025_1120	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST90020025_1122	Waist-to-hip ratio adjusted for BMI	3.000000e-12
GCST90020027_1398	Waist-hip index	9.000000e-11
GCST90020027_1399	Waist-hip index	2.000000e-08
GCST90020027_1401	Waist-hip index	4.000000e-08
GCST90020027_1402	Waist-hip index	2.000000e-08
GCST90020027_1404	Waist-hip index	3.000000e-12

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004327	electrocardiography
EFO:0004587	lymphocyte count
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3236 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

52 potent at pChembl≥5 of 100 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.89	IC50	130	nM	CHEMBL4750435
6.67	IC50	216	nM	CHEMBL1408081
6.50	IC50	313	nM	CHEMBL1407368
6.49	IC50	325	nM	CHEMBL1701224
6.48	IC50	334	nM	CHEMBL1701224
6.33	IC50	471	nM	CHEMBL1320181
6.15	IC50	714	nM	CHEMBL1390354
6.10	IC50	800	nM	CHEMBL2396718
6.04	IC50	916	nM	CHEMBL1572439
6.02	IC50	953	nM	CHEMBL1704862
6.01	IC50	975	nM	CHEMBL601167
6.00	Ki	1000	nM	CHEMBL4638054
6.00	IC50	1000	nM	CHEMBL1456664
5.95	IC50	1130	nM	CHEMBL1438889
5.83	IC50	1490	nM	CHEMBL1719149
5.79	IC50	1630	nM	CHEMBL1492305
5.78	IC50	1680	nM	CHEMBL1414679
5.78	IC50	1650	nM	CHEMBL1443268
5.69	IC50	2030	nM	CHEMBL1373132
5.66	IC50	2200	nM	CHEMBL1721618
5.66	IC50	2200	nM	CHEMBL324232
5.64	IC50	2300	nM	CHEMBL108721
5.63	IC50	2360	nM	CHEMBL1417070
5.62	IC50	2400	nM	CHEMBL2396719
5.62	IC50	2410	nM	CHEMBL1424189
5.60	IC50	2520	nM	CHEMBL1609429
5.58	IC50	2600	nM	CHEMBL1550429
5.57	IC50	2690	nM	CHEMBL1562411
5.56	IC50	2780	nM	CHEMBL1526088
5.55	IC50	2810	nM	CHEMBL1722719
5.55	IC50	2790	nM	CHEMBL1373210
5.54	IC50	2910	nM	CHEMBL1371816
5.50	IC50	3130	nM	CHEMBL1327648
5.46	IC50	3430	nM	CHEMBL1439815
5.42	IC50	3850	nM	CHEMBL1415285
5.32	IC50	4760	nM	CHEMBL1732016
5.29	IC50	5080	nM	CHEMBL1718018
5.28	IC50	5220	nM	CHEMBL4290098
5.19	IC50	6400	nM	CHEMBL5629904
5.12	IC50	7600	nM	CHEMBL1724311
5.12	IC50	7560	nM	CHEMBL1724482
5.12	IC50	7630	nM	CHEMBL1724547
5.11	IC50	7860	nM	CHEMBL1729688
5.11	IC50	7690	nM	CHEMBL1730304
5.10	IC50	7990	nM	CHEMBL1709810
5.09	IC50	8200	nM	CHEMBL5630329
5.08	IC50	8240	nM	CHEMBL1487870
5.07	IC50	8520	nM	CHALCOMORACIN
5.03	IC50	9350	nM	CHEMBL1718472
5.03	IC50	9280	nM	CHEMBL1413629

PubChem BioAssay actives

10 with measured affinity, of 54 total; 10 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[1-(4-methoxyphenyl)-3-(2-oxochromen-7-yl)pyrrolo[2,3-b]pyridin-5-yl]benzoic acid	1706924: Inhibition of PTPN12 (unknown origin) pre-incubated for 20 mins followed by fluorescence substrate addition and measured after 120 mins by DiFMUP assay	ic50	0.1300	uM
3-[2-(3-chlorophenyl)ethynyl]-6-hydroxy-2-[4-[2-oxo-2-(propylamino)ethoxy]phenyl]-1-benzofuran-5-carboxylic acid	755773: Inhibition of recombinant PTP-PEST (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	0.8000	uM
4-[(E)-3-(3-nitrophenyl)-3-oxoprop-1-enyl]benzoic acid	1664546: Competitive inhibition of PTP-PEST (unknown origin) assessed as inhibition constant using varying level of pNPP as substrate by Lineweaver-Burk plot analysis	ki	1.0000	uM
(2R)-2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzofuran-11-yl)phenoxy]-3-phenylpropanoic acid	164853: The compound was tested in vitro for the inhibitory activity against Protein tyrosine phosphatase PEST (SH-PTP1) (human PTPases.)	ic50	2.2000	uM
2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetic acid	164853: The compound was tested in vitro for the inhibitory activity against Protein tyrosine phosphatase PEST (SH-PTP1) (human PTPases.)	ic50	2.3000	uM
3-[2-(3-chlorophenyl)ethynyl]-2-[4-[2-(cyclopropylamino)-2-oxoethoxy]phenyl]-6-hydroxy-1-benzofuran-5-carboxylic acid	755773: Inhibition of recombinant PTP-PEST (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	2.4000	uM
8-[(1R,5S,6R)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one	1402913: Inhibition of PTP-PEST (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis	ic50	5.2200	uM
5-[(3-phenylphenyl)methyl-(4-phenylphenyl)sulfonylamino]-1-benzofuran-2-carboxylic acid	2133929: Inhibition of N-terminal His-tagged PTPN12 catalytic domain (1 to 294 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells	ic50	6.4000	uM
4-[[4-[(E)-[6-acetyl-5-[4-(dimethylamino)phenyl]-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2-ylidene]methyl]phenoxy]methyl]benzoic acid	2133929: Inhibition of N-terminal His-tagged PTPN12 catalytic domain (1 to 294 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells	ic50	8.2000	uM
[(1R,2S,6S)-2-[2,6-dihydroxy-4-(6-hydroxy-1-benzofuran-2-yl)phenyl]-6-(2,4-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]methanone	1402913: Inhibition of PTP-PEST (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis	ic50	8.5200	uM

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases methylation, affects expression	4
Valproic Acid	affects expression, decreases expression, increases expression, increases methylation	4
trichostatin A	affects cotreatment, decreases expression	2
sodium arsenite	affects methylation, increases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Estradiol	affects cotreatment, increases expression, affects expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
geldanamycin	increases expression	1
N(6)-(delta(2)-isopentenyl)adenine	increases expression	1
2,4,6-tribromophenol	decreases expression	1
lead acetate	decreases expression, affects cotreatment	1
decabromobiphenyl ether	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
afimoxifene	decreases expression, decreases reaction	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
zinc protoporphyrin	affects cotreatment, decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
K 7174	increases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
bisphenol B	increases expression	1

ChEMBL screening assays

18 unique, capped per target: 13 binding, 4 admet, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1738078	Functional	PUBCHEM_BIOASSAY: SAR Selectivity Analysis of small molecule inhibitors of PEST using pCAP in a fluorescence assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1779, AID1784, AID2135]	PubChem BioAssay data set
CHEMBL2161836	Binding	Inhibition of PTP-PEST expressed in Escherichia coli BL21 using pNPP substrate	Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. — J Med Chem
CHEMBL4625402	ADMET	Inhibition of PTP-PEST (unknown origin)	A chalcone derivative binds a putative allosteric site of YopH: Inhibition of a virulence factor of Yersinia. — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7Z2	Abcam Raji PTPN12 KO	Cancer cell line	Male
CVCL_B9ZT	Abcam THP-1 PTPN12 KO	Cancer cell line	Male
CVCL_C7BH	Abcam PC-3 PTPN12 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00114829	PHASE4	UNKNOWN	Preoperative Assessment of Colon Tumor
NCT00114842	PHASE4	COMPLETED	Magnetic Resonance (MR) Colonography With Fecal Tagging
NCT00114946	PHASE4	TERMINATED	A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00122720	PHASE4	COMPLETED	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
NCT00129870	PHASE4	TERMINATED	CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00138060	PHASE4	COMPLETED	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00216424	PHASE4	TERMINATED	Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00327093	PHASE4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00332943	PHASE4	COMPLETED	MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil
NCT00441311	PHASE4	COMPLETED	Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00460837	PHASE4	WITHDRAWN	Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
NCT00473980	PHASE4	COMPLETED	Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00488904	PHASE4	COMPLETED	Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00502671	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
NCT00559676	PHASE4	COMPLETED	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031	PHASE4	COMPLETED	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00626054	PHASE4	COMPLETED	Comparison of Two Methods of Administration of a PEG Solution
NCT00812864	PHASE4	COMPLETED	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00868569	PHASE4	UNKNOWN	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
NCT00868816	PHASE4	COMPLETED	Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
NCT00874406	PHASE4	UNKNOWN	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00928928	PHASE4	COMPLETED	Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer
NCT00942461	PHASE4	COMPLETED	Inflammatory Response in Laparoscopic and Open Colectomy
NCT01023633	PHASE4	UNKNOWN	OPTIMOX1 in Chinese mCRC Patients
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01315990	PHASE4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01493713	PHASE4	COMPLETED	Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01609660	PHASE4	COMPLETED	Impact of Probiotics on the Intestinal Microbiota
NCT01641458	PHASE4	COMPLETED	Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
NCT01689792	PHASE4	COMPLETED	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
NCT01695772	PHASE4	COMPLETED	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01695863	PHASE4	COMPLETED	Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
NCT01706822	PHASE4	TERMINATED	Radial Reload Laparoscopic LAR Case Series
NCT01740947	PHASE4	TERMINATED	Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?
NCT01831310	PHASE4	COMPLETED	Nutrition for Colorectal Cancer Patients and Neutrophil Functions
NCT01841294	PHASE4	UNKNOWN	NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery
NCT01959061	PHASE4	UNKNOWN	Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
NCT02032953	PHASE4	UNKNOWN	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
NCT02567331	PHASE4	COMPLETED	A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer